MeiraGTx Holdings PLC
MGTX7.430USD
+0.230+3.19%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
597.96MMarket Cap
LossP/E TTM
More Details of MeiraGTx Holdings PLC Company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
MeiraGTx Holdings PLC Info
Ticker SymbolMGTX
Company nameMeiraGTx Holdings PLC
IPO dateJun 08, 2018
CEOForbes (Alexandria)
Number of employees381
Security typeOrdinary Share
Fiscal year-endJun 08
Address655 Third Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10017
Phone16468607985
Websitehttps://meiragtx.com/
Ticker SymbolMGTX
IPO dateJun 08, 2018
CEOForbes (Alexandria)
Company Executives of MeiraGTx Holdings PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
+174510.00%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.09M
+169762.00%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
682.92K
+59625.00%
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
168.34K
+31820.00%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+75000.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
52.08K
+25930.00%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
+174510.00%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.09M
+169762.00%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
682.92K
+59625.00%
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
168.34K
+31820.00%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+75000.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sanofi SA
15.15%
Perceptive Advisors LLC
12.77%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
Other
53.54%
Shareholders
Shareholders
Proportion
Sanofi SA
15.15%
Perceptive Advisors LLC
12.77%
Johnson & Johnson Innovation-JJDC, Inc.
8.25%
Adage Capital Management, L.P.
5.20%
Prosight Capital
5.08%
Other
53.54%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.91%
Corporation
16.02%
Private Equity
12.77%
Venture Capital
8.29%
Investment Advisor
7.72%
Individual Investor
4.74%
Investment Advisor/Hedge Fund
4.39%
Research Firm
2.26%
Pension Fund
0.09%
Other
16.80%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
236
50.32M
62.51%
-4.52M
2025Q3
228
52.30M
65.02%
+2.51M
2025Q2
231
67.71M
84.26%
+4.10M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sanofi SA
12.20M
15.15%
--
--
Sep 30, 2025
Perceptive Advisors LLC
10.28M
12.77%
-2.35M
-18.57%
Dec 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.25%
--
--
Sep 30, 2025
Adage Capital Management, L.P.
4.18M
5.2%
-1.85M
-30.66%
Sep 30, 2025
Prosight Capital
4.09M
5.08%
-497.91K
-10.85%
Sep 30, 2025
Rubric Capital Management LP
3.73M
4.63%
--
--
Sep 30, 2025
683 Capital Management LLC
2.63M
3.26%
-65.00K
-2.42%
Sep 30, 2025
Millennium Management LLC
2.56M
3.18%
+1.78M
+226.16%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.39M
2.97%
-94.99K
-3.82%
Sep 30, 2025
J. Goldman & Co., L.P.
1.80M
2.24%
-243.64K
-11.92%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
Goldman Sachs Innovate Equity ETF
0.06%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
View more
iShares Micro-Cap ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
Goldman Sachs Innovate Equity ETF
Proportion0.06%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.02%
SPDR S&P International Small Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
